Rivas BC, Cedillo FVM

Language: Spanish
References: 23
Page: 252-260
PDF size: 333.65 Kb.

ABSTRACT

Bisphosphonates are a group medications that have been used for the last decades for the treatment of conditions that are characterized by bone loss or destruction, cancer, menopause and non-malignant bone diseases, which is why it is very important to make a broad and correct medical history to avoid the possible complications in the healing phase of dental surgical treatments. When treating a patient with a history of this drug we should know the pharmacokinetics and pharmacodynamics to be able to plan the pre, trans and postoperative treatment of patients mainly subject to dental extractions, which is why currently this type of patients can be classified according to the results of the laboratory test of the C-Telopeptide protein. Once the patient’s risk has been determined according to the results of this test, an effective and safe treatment plan can be started for the patient in which the necessary precautions are taken to not develop a mandibular or maxillary osteonecrosis. We present a case of a patient with a history of bisphosphonates where the treatment is done according to the current guidelines for treating this type of patients.

REFERENCES

1. Lisboa MG, Puricelli E, Fasolo PM, Ponzoni D, Espíndola BC. Mandibular avascular osteonecrosis caused by bisphosphonate-a case report and brief review. Rev Odonto Ciênc. 2009; 24 (4): 435-438.

2. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R et al. Osteonecrosis of the mandibular maxila associated with the use of new generation bisphosphonates. Laryngoscope. 2006; 116 (1): 115-120.

3. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod. 2005; 31 (11): 831-834.

4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23: 8580-8587.

5. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated 6. With intravenous bisphosphonates. Ann Oncol. 2006; 17: 897-907.

6. Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dent Res. 2006; 85: 584-595.

7. Stewart P. Effects of bisphosphonates for osteoporosis on oral health. Dental Nursing. 2014; 10 (5): 270-273.

8. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144: 753-761.

9. Weeda L Jr. Bisphosphonate related osteonecrosis of the jaws: a review and update. J Tenn Dent Assoc. 2009; 89 (82): 16-19.

10. Black DS, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group. J Clin Endocrinol Metab. 2000; 85: 4118-4124.

11. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65 (3): 415-423.

12. Lo JC, O’Ryan FS, Gordon NP et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxilofac Surg. 2010; 68: 243-253.

13. Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM et al. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int. 2010; 21 (5): 847-853.

14. Pasoff M. C-terminal cross-linking telopeptide as a serologic marker for bisphosphonate -related osteonecrosis of the jaw: review of 2 cases. J Can Dent Assoc. 2013; 79 (3): d51.

15. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67 (6): 1167-1173.

16. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis risk factor, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65 (12): 2397-2410.

17. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008; 66: 1320-1321.

18. Sosa HM, Gómez TR, Bagán SJ, Díaz CM, Díez PA, Jódar GE y cols. Osteonecrosis de los maxilares: Documento de consenso. Rev Osteoporos Metab Miner. 2009; 1: 141-151.

19. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg. 2014; 72: 1938-1956.

20. Rustemeyer J, Melenberg A, Junker K, Sari-Rieger A. Osteonecrosis of the maxilla related to long-standing methamphetamine abuse: a possible new aspect in the etiology of osteonecrosis of the jaw. Oral Maxillofac Surg. 2014; 18 (2): 237-241.

21. Wei X, Pushalkar S, Estilo C, Wong C, Farooki A, Fornier M et al. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2012; 18 (6): 602-612.

22. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005; 32 (11): 1123-1128.

23. Katz J, Ordoveza P. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature. Quintessence Int. 2014; 45 (8): 685-690.